Published in Med Clin (Barc) on February 06, 1993
[Vitiligo associated with the acquired immunodeficiency syndrome]. Med Clin (Barc) (1994) 0.75
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med (1993) 4.88
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
[Treatment and prophylaxis of the principal infections associated with the human immunodeficiency virus]. Med Clin (Barc) (1993) 1.96
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis (2008) 1.86
[An esophageal ulcer due to cytomegalovirus in a female patient infected with the human immunodeficiency virus without serious immunosuppression: is this an acquired immunodeficiency syndrome?]. Med Clin (Barc) (1992) 1.40
[Antiretroviral treatment against HIV]. Med Clin (Barc) (1995) 1.39
[Interrelationship between the duration of HIV infection, viral load and CD4 positive lymphocyte count]. Med Clin (Barc) (1998) 1.38
[Serologic activity against retrovirus in patients with Sjögren syndrome]. Med Clin (Barc) (1993) 1.38
[Rapid and slow progression of the infection by the type 1 human immunodeficiency virus in a population of seropositive subjects in Madrid]. Med Clin (Barc) (1996) 1.38
Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J Clin Microbiol (2000) 1.35
Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr (2001) 1.33
Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol (2000) 1.32
Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. AIDS (1993) 1.23
Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses (2001) 1.17
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS (2000) 1.13
Idiopathic CD4+ T-lymphocytopenia. Lancet (1992) 1.12
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS (2000) 1.05
Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis (1996) 1.04
Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. Clin Exp Immunol (2009) 1.04
Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat (2011) 1.00
Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol (1999) 0.98
Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2000) 0.98
Kaposi's sarcoma and disseminated tuberculosis in HIV-negative individual. Lancet (1992) 0.97
Virological failure and adherence to antiretroviral therapy in HIV-infected patients. AIDS (1998) 0.97
Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquir Immune Defic Syndr (2000) 0.95
First case of HIV-1 group O infection in Spain. Vox Sang (1996) 0.95
Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. Clin Microbiol Infect (2001) 0.93
Viral replication in patients with multiple hepatitis virus infections. Gastroenterology (1994) 0.90
Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat (2004) 0.90
Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. J Hum Virol (2000) 0.89
Short-term response to indinavir in patients with advanced HIV disease with prior heavy exposure to nucleoside analogues. AIDS (1997) 0.87
Clinical benefit of interventions driven by therapeutic drug monitoring. HIV Med (2005) 0.86
Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy. AIDS (1997) 0.86
Nucleotide sequence and restriction fragment-length polymorphism analysis of human T-cell lymphotropic virus type II (HTLV-II) in southern Europe: evidence for the HTLV-IIa and HTLV-IIb subtypes. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.86
Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med (2008) 0.86
[Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir]. Rev Esp Med Nucl (2006) 0.85
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in Europe. Arch Intern Med (1995) 0.85
Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. Clin Exp Immunol (2007) 0.84
Can early failure with nevirapine be rescued with efavirenz? J Acquir Immune Defic Syndr (2000) 0.83
Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antivir Ther (1998) 0.83
Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat (2006) 0.83
Significance of indeterminate reactivity to human T-cell lymphotropic virus in western blot analysis of individuals at risk. Eur J Clin Microbiol Infect Dis (1997) 0.83
The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. J Infect (1998) 0.83
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. AIDS (1999) 0.81
[HIV infection in old age: an epidemiological and clinical study in 42 patients in the Community of Madrid]. Rev Clin Esp (1997) 0.78
Impact of immunosuppression caused by HIV infection on the replication of hepatitis C virus. Vox Sang (1995) 0.78
High rate of indeterminate reactivity to HTLV in western blot analysis of Spanish blood donors. Vox Sang (1996) 0.78
Detection of HTLV-II proviral sequences in HIV-immunosuppressed patients with HTLV indeterminate serological patterns. J Infect (1998) 0.78
Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. AIDS (2000) 0.78
Fatal varicella hepatitis in a patient with AIDS. J Infect (1992) 0.77
Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. AIDS (2000) 0.77
[Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program]. Med Clin (Barc) (2000) 0.77
[Xanthomonas maltophilia endocarditis in an AIDS patient]. Med Clin (Barc) (1994) 0.76
Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. HTLV Spanish Study Group. Eur J Epidemiol (1996) 0.76
Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. Clin Microbiol Infect (2003) 0.76
[Opportunistic episodes in patients infected with the human immunodeficiency virus during the first 6 months of HAART]. Med Clin (Barc) (2001) 0.76
Hepatitis C virus genotypes in different risk populations in Spain. The Hepatitis-HIV Spanish Study Group. J Infect Dis (1996) 0.75
More severe course of delta hepatitis in HIV-infected patients [L]. Genitourin Med (1995) 0.75
Prevalence of zidovudine-resistant HIV-1 among rapid progressors. AIDS (1996) 0.75
Higher antiviral activity of antiretroviral regimens including protease inhibitors. AIDS (1999) 0.75
HIV-1 progression in hepatitis-C-infected drug users. Lancet (2001) 0.75
High alcohol intake and slow progression to AIDS. Genitourin Med (1996) 0.75
Prevention of nevirapine-associated rash. Lancet (2001) 0.75
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? AIDS (2000) 0.75
Role of nonnucleosides in the development of HAART-related lipid disturbances. J Acquir Immune Defic Syndr (2001) 0.75
Avoiding false-negative results for HTLV-II using new serological assays. Am J Med (1995) 0.75
HTLV-I and HTLV-II in Africans. Genitourin Med (1995) 0.75
[Rapid progression to AIDS in a patient with infection from a strain of syncytium forming HIV-1]. Med Clin (Barc) (1995) 0.75
[Residual risk of retrovirus transmission by transfusions]. Rev Clin Esp (1995) 0.75
[Serotypes of the human immunodeficiency virus type 1 in Madrid]. Med Clin (Barc) (1997) 0.75
[HTLV-I]. Rev Clin Esp (1994) 0.75
[HIV-2]. Med Clin (Barc) (1994) 0.75
[Clinical syndromes in HIV infection (1st of 2 parts)]. An Med Interna (1992) 0.75
Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. J Viral Hepat (2007) 0.75
Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. J Viral Hepat (2010) 0.75
[Retrovirus: diagnostic tests and their interpretation (II). HIV-2, HTLV-I, and HTLV-II infection]. Med Clin (Barc) (1993) 0.75
[Retrovirus: diagnostic tests and their interpretation (I). Generalities and infection by HIV-1]. Med Clin (Barc) (1993) 0.75
[Lethal meningitis caused by varicella-zoster virus in a patient with AIDS]. Rev Clin Esp (1992) 0.75
[The tuberculosis of AIDS: a new tuberculosis?]. An Med Interna (1992) 0.75
HIV-2 infection in high-risk individuals with indeterminate HIV-1 western blot analysis: a serologic surveillance. Vox Sang (1992) 0.75
[Frequency and characteristics of patients treated with zidovudine and absence of progression of HIV infection]. An Med Interna (1997) 0.75
[Changes in the spectrum of the diseases in patients hospitalized with HIV infection]. Med Clin (Barc) (1993) 0.75
[Viral load and monitoring of antiretroviral treatment]. Rev Clin Esp (1996) 0.75
[Which HIV-infected individuals develop AIDS faster?]. Rev Clin Esp (1991) 0.75
[Prevention of transfusional infection caused by human immunodeficiency virus]. Med Clin (Barc) (1991) 0.75
[Clinical syndromes in HIV infection (part 2)]. An Med Interna (1992) 0.75
[A multicenter study of infection with human immunodeficiency virus type-2 (HIV-2) in Spain (1991). The Spanish Group for the Study of HIV-2]. Med Clin (Barc) (1993) 0.75
[The rapid and slow progression of HIV infection]. Rev Clin Esp (1995) 0.75
[Acute polyradiculomyelitis from cytomegalovirus in a patient with the acquired immunodeficiency syndrome]. Med Clin (Barc) (1992) 0.75
[Quantification of viremia in patients infected with human immunodeficiency virus with different degrees of immunosuppression]. Rev Clin Esp (1997) 0.75
[Evaluation of various criteria for the interpretation of western blot for the diagnosis of human immunodeficiency virus infection. Spanish Group for the Study of HIV-2]. Med Clin (Barc) (1993) 0.75
[Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus]. Med Clin (Barc) (1995) 0.75
[Strategies for the prevention of human immunodeficiency virus infection]. Rev Clin Esp (1995) 0.75
Insufficiencies of the new WHO western blot criteria in the diagnosis of HIV-1 and HIV-2 infections. Vox Sang (1992) 0.75
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. An Med Interna (1996) 0.75
[The seroepidemiology of infection with the human immunodeficiency virus type 2 (HIV-2) in Spain (1990). The Spanish Group for the Study and Follow-up of HIV-2 Infection]. Med Clin (Barc) (1992) 0.75